文献速递消化与肝胆胰病理细胞病理与分子病理

胰腺导管腺癌FNA涂片DNA质量优于FFPE组织:配对样本KRAS检测比较

FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA: Comparison of targeted KRAS amplification and genotyping in matched preresection and postresection samples.
PubMed 文献 · Cancer Cytopathol · 2017-10-12

本研究比较了30对匹配的胰腺导管腺癌FNA涂片与FFPE组织的DNA产量、扩增功能及KRAS突变检出。FNA涂片单位核面积DNA产量更高,KRAS codon 12突变检出率77%(23/30)高于FFPE的57%(17/30),一致性74%。结论认为FNA是更优的DNA来源,适用于术前术后分子分析。

要点

  • FNA涂片单位核面积DNA产量高于FFPE组织,更适合作分子检测样本。
  • FNA涂片KRAS codon 12突变检出率77%,高于配对FFPE的57%。
  • 两种样本KRAS突变一致性为74%,未见codon 13或61突变。

核心结论

  • FNA涂片是胰腺导管腺癌更优的DNA来源,可作为术前术后分子分析的重要资源。

研究设计与样本

  • 回顾性比较30对匹配的单张FNA涂片与宏观切割的FFPE卷(2个5μm卷)。
  • 检测项目包括核面积(数字图像分析)、DNA产量(NanoDrop分光光度法和Quantus荧光法)及KRAS扩增的PCR阈值循环数。
  • KRAS codon 12/13和61变异通过荧光熔解曲线分析检测,随后进行Sanger测序。

主要发现

  • 尽管核面积相似,两种DNA定量方法均显示FNA涂片单位核面积DNA产量更高。
  • KRAS codon 12突变在FNA涂片中检出23/30(77%),在配对FFPE中检出17/30(57%),一致性率为74%。
  • 未检测到KRAS codon 13或61突变。

关键数值与推荐

  • FNA涂片KRAS codon 12突变检出率77%(23/30),FFPE为57%(17/30),一致性74%。
  • KRAS codon 13和61突变未检出。

临床怎么用

  • 胰腺导管腺癌分子检测可优先考虑FNA涂片样本,以提高DNA产量和KRAS突变检出。
  • 术前FNA样本与术后FFPE样本均可用于KRAS分型,但FNA涂片更具优势。

局限性

  • 回顾性研究,样本量为30对匹配样本。
  • 仅评估KRAS codon 12/13和61,未涉及其他基因或突变位点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The current study was conducted to compare DNA yield, including normalization to nuclear area, DNA amplification functionality, and detection of KRAS mutations between matched fine-needle aspiration (FNA) specimens and pancreatic resections diagnostic of pancreatic ductal adenocarcinoma. METHODS: A retrospective sample of 30 matched single FNA smears and macrodissected formalin-fixed, paraffin-embedded (FFPE) curls (2 5-μm curls) were compared by measuring the following: nuclear area (via digital image analysis), DNA yield (via NanoDrop spectrophotometry and Quantus fluorometry), and polymerase chain reaction threshold cycles for KRAS amplifications. Variants in KRAS codons 12/13 and 61 were detected by fluorescent melt curve analyses, followed by Sanger DNA sequencing. RESULTS: Despite a similar nuclear area, FNA smears yielded greater DNA per nuclear area via 2 DNA quantification methods. KRAS codon 12 mutations were detected in 23 of 30 FNA specimens (77%) compared with 17 of 30 matched FFPE specimens (57%), for a concordance rate of 74%. No KRAS codon 13 or 61 mutations were detected. CONCLUSIONS: FNA specimens are a more optimal source of DNA, and represent an important resource in the preresection and postresection molecular analysis of pancreatic ductal adenocarcinoma. Cancer Cytopathol 2017;125:838-47. © 2017 American Cancer Society.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Hartley CP, Mahajan AM, Selvaggi SM, et al. FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA: Comparison of targeted KRAS amplification and genotyping in matched preresection and postresection samples. Cancer Cytopathol. 2017. PMID: 29024530. doi:10.1002/cncy.21935

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。